A homolog of formyl peptide receptor-like 1 (FPRL1) inhibitor from Staphylococcus aureus (FPRL1 inhibitory protein) that inhibits FPRL1 and FPR

Journal of Immunology

Volumn 183, Issue 10, 2009, Pages 6569-6578

  Prat, Cristina ^a,b   Haas, Pieter Jan ^a   Bestebroer, Jovanka ^a   De Haas, Carla J C ^a   Van Strijp, Jos A G ^a   Van Kessel, Kok P M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

FORMYLPEPTIDE RECEPTOR; FORMYLPEPTIDE RECEPTOR LIKE 1; FORMYLPEPTIDE RECEPTOR LIKE 1 INHIBITORY PROTEIN; FORMYLPEPTIDE RECEPTOR LIKE 1 INHIBITORY PROTEIN LIKE PROTEIN; INHIBITOR PROTEIN; PHENYLALANINE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; CALCIUM MOBILIZATION; CELL STRAIN HEK293; HUMAN; HUMAN CELL; NEUTROPHIL CHEMOTAXIS; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; SEQUENCE ANALYSIS; SEQUENCE HOMOLOGY; STAPHYLOCOCCUS AUREUS;

AMINO ACID SEQUENCE; BACTERIAL PROTEINS; CHEMOTAXIS; HUMANS; MOLECULAR SEQUENCE DATA; NEUTROPHILS; PEPTIDES; RECEPTOR, ANAPHYLATOXIN C5A; RECEPTORS, FORMYL PEPTIDE; RECEPTORS, LIPOXIN; STAPHYLOCOCCUS AUREUS;

EID: 77952814319     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0801523     Document Type: Article

References (46)

1. Le, Y., J. J. Oppenheim, and J. M. Wang. 2001. Pleiotropic roles of formyl peptide receptors. Cytokine Growth Factor Rev. 12: 91-105.
2. Le, Y., P. M. Murphy, and J. M. Wang. 2002. Formyl-peptide receptors revisited. Trends Immunol. 23: 541-548.
3. Ye, R. D., F. Boulay, J. M. Wang, C. Dahlgren, C. Gerard, M. Parmentier, C. N. Serhan, and P. M. Murphy. 2009. International Union of Basic and Clinical Pharmacology, LXXIII: Nomenclature for the formyl peptide receptor (FPR) family. Pharmacol. Rev. 61: 119-161.
4. Schiffmann, E., B. A. Corcoran, and S. M. Wahl. 1975. N-formylmethionyl peptides as chemoattractants for leucocytes. Proc. Natl. Acad. Sci. USA 72: 1059-1062.
5. Fu, H., J. Karlsson, J. Bylund, C. Movitz, A. Karlsson, and C. Dahlgren. 2006. Ligand recognition and activation of formyl peptide receptors in neutrophils. J. Leukocyte Biol. 79: 247-256.
6. Prossnitz, E. R., and R. D. Ye. 1997. The N-formyl peptide receptor: a model for the study of chemoattractant receptor structure and function. Pharmacol. Ther. 74: 73-102.
7. Migeotte, I., D. Communi, and M. Parmentier. 2006. Formyl peptide receptors: a promiscuous subfamily of G protein-coupled receptors controlling immune responses. Cytokine Growth Factor Rev. 17: 501-519.
8. Mills, J. S. 2006. Peptides derived from HIV-1, HIV-2, Ebola virus, SARS coronavirus and coronavirus 229E exhibit high affinity binding to the formyl peptide receptor. Biochim. Biophys. Acta 1762: 693-703.
9. Iribarren, P., Y. Zhou, J. Hu, Y. Le, and J. M. Wang. 2005. Role of formyl peptide receptor-like 1 (FPRL1/FPR2) in mononuclear phagocyte responses in Alzheimer disease. Immunol. Res. 31: 165-176.
10. Lowy, F. D. 1998. Staphylococcus aureus infections. N. Engl. J. Med. 339: 520-532.
11. Sibbald, M. J., A. K. Ziebandt, S. Engelmann, M. Hecker, A. de Jong, H. J. Harmsen, G. C. Raangs, I. Stokroos, J. P. Arends, J. Y. Dubois, and J. M. van Dijl. 2006. Mapping the pathways to staphylococcal pathogenesis by comparative secretomics. Microbiol. Mol. Biol. Rev. 70: 755-788.
12. Foster, T. J. 2005. Immune evasion by staphylococci. Nat. Rev. Microbio. 3: 948-958.
13. Nizet, V. 2007. Understanding how leading bacterial pathogens subvert innate immunity to reveal novel therapeutic targets. J. Allergy Clin. Immunol. 120: 13-22.
14. Rooijakkers, S. H. M., K. P. M. van Kessel, and J. A. G. van Strijp. 2005. Staphylococcal innate immune evasion. Trends Microbiol. 13: 596-601.
15. Bestebroer, J., M. J. J. G. Poppelier, L. H. Ulfman, P. J. Lenting, C. V. Denis, K. P. M. van Kessel, J. A. G. van Strijp, and C. J. C. de Haas. 2007. Staphylococcal superantigen-like 5 binds PSGL-1 and inhibits P-selectin-mediated neutrophil rolling. Blood 109: 2936-2943.
16. Rooijakkers, S. H. M., M. Ruyken, A. Roos, M. R. Daha, J. S. Presanis, R. B. Sim, W. J. B. van Wamel, K. P. M. van Kessel, and J. A. G. van Strijp. 2005. Immune evasion by a staphylococcal complement inhibitor that acts on C3 convertases. Nat. Immunol. 6: 920-927.
17. de Haas, C. J. C., K. E. Veldkamp, A. Peschel, F. Weerkamp, W. J. B. van Wamel, H. C. Heezius, M. J. J. G. Poppelier, K. P. van Kessel, and J. A. van Strijp. 2004. Chemotaxis inhibitory protein of Staphylococcus aureus, a bacterial anti-inflammatory agent. J. Exp. Med. 199: 687-695.
18. Prat, C., J. Bestebroer, C. J. C. de Haas, J. A. G. van Strijp, and K. P. M. van Kessel. 2006. A new staphylococcal anti-inflammatory protein that antagonizes the formyl peptide receptor-like 1. J. Immunol. 177: 8017-8026. (Pubitemid 44846319)
19. Hu, J. Y., Y. Le, W. Gong, N. M. Dunlop, J. L. Gao, P. M. Murphy, and J. M. Wang. 2001. Synthetic peptide MMK-1 is a highly specific chemotactic agonist for leukocyte FPRL1. J. Leukocyte Biol. 70: 155-161.
20. 4 receptors and is an agonist for the orphan monocyte-expressed chemoattractant receptor FPRL2. J. Biol. Chem. 276: 21585-21593.
21. 42 activates a G-protein-coupled chemoattractant receptor, FPR-Like-1. J. Neurosci. 21: RC123.
22. 106-126 is a chemotactic agonist for the G protein-coupled receptor formyl peptide receptor-like 1. J. Immunol. 166: 1448-1451.
23. Haas, P. J., C. J. C. de Haas, W. Kleibeuker, M. J. J. G. Poppelier, K. P. van Kessel, J. A. W. Kruijtzer, R. M. J. Liskamp, and J. A. van Strijp. 2004. N-terminal residues of the chemotaxis inhibitory protein of Staphylococcus aureus are essential for blocking formylated peptide receptor but not C5a receptor. J. Immunol. 173: 5704-5711.
24. Veldkamp, K. E., H. C. Heezius, J. Verhoef, J. A. van Strijp, and K. P. van Kessel. 2000. Modulation of neutrophil chemokine receptors by Staphylococcus aureus supernate. Infect. Immun. 68: 5908-5913.
25. Postma, B., W. Kleibeuker, M. J. Poppelier, M. Boonstra, K. P. van Kessel, J. A. van Strijp, and C. J. de Haas. 2005. Residues 10-18 within the C5a receptor N terminus compose a binding domain for chemotaxis inhibitory protein of Staphylococcus aureus. J. Biol. Chem. 280: 2020-2027.
26. 4. Scand. J. Immunol. 56: 470-476.
27. 4 receptor. Blood 95: 1810-1818.
28. Murdoch, C., and A. Finn. 2000. Chemokine receptors and their role in inflammation and infectious diseases. Blood 95: 3032-3043. (Pubitemid 30321151)
29. Jongerius, I., J. Kohl, M. K. Pandey, M. Ruyken, K. P. van Kessel, J. A. van Strijp, and S. H. Rooijakkers. 2007. Staphylococcal complement evasion by various convertase-blocking molecules. J. Exp. Med. 204: 2461-2471.
30. van Wamel, W. J., S. H. Rooijakkers, M. Ruyken, K. P. van Kessel, and J. A. van Strijp. 2006. The innate immune modulators staphylococcal complement inhibitor and chemotaxis inhibitory protein of Staphylococcus aureus are located on β-hemolysin-converting bacteriophages. J. Bacteriol. 188: 1310-1315.
31. Freer, R. J., A. R. Day, J. A. Radding, E. Schiffmann, S. Aswanikumar, H. J. Showell, and E. L. Becker. 1980. Further studies on the structural requirements for synthetic peptide chemoattractants. Biochemistry 19: 2404-2410.
32. Dalpiaz, A., M. E. Ferretti, G. Vertuani, S. Traniello, A. Scatturin, and S. Spisani. 2002. C- and N-terminal residue effect on peptide derivatives' antagonism toward the formyl-peptide receptor. Eur. J. Pharmacol. 436: 187-196.
33. Dalpiaz, A., M. E. Ferretti, R. Pecoraro, E. Fabbri, S. Traniello, A. Scatturin, and S. Spisani. 1999. Phe-D-Leu-Phe-D-Leu-Phe derivatives as formylpeptide receptor antagonists in human neutrophils: cellular and conformational aspects. Biochim. Biophys. Acta 1432: 27-39.
34. Wenzel-Seifert, K., L. Grunbaum, and R. Seifert. 1991. Differential inhibition of human neutrophil activation by cyclosporins A, D, and H: cyclosporin H is a potent and effective inhibitor of formyl peptide-induced superoxide formation. J. Immunol. 147: 1940-1946.
35. Wenzel-Seifert, K., and R. Seifert. 1993. Cyclosporin H is a potent and selective formyl peptide receptor antagonist: comparison with N-t-butoxycarbonyl-L-phenylalanyl-L-leucyl-L-phenylalanyl-L-leucyl-L- phenylalanine and cyclosporins A, B, C, D, and E. J. Immunol. 150: 4591-4599.
36. Stenfeldt, A. L., J. Karlsson, C. Wenneras, J. Bylund, H. Fu, and C. Dahlgren. 2007. The non-steroidal anti-inflammatory drug piroxicam blocks ligand binding to the formyl peptide receptor but not the formyl peptide receptor like 1. Biochem. Pharmacol. 74: 1050-1056.
37. Bae, Y. S., H. Y. Lee, E. J. Jo, J. I. Kim, H. K. Kang, R. D. Ye, J. Y. Kwak, and S. H. Ryu. 2004. Identification of peptides that antagonize formyl peptide receptor- like 1-mediated signaling. J. Immunol. 173: 607-614.
38. Shin, E. H., H. Y. Lee, S. D. Kim, S. H. Jo, M. K. Kiin, K. S. Park, H. Lee, and Y. S. Bae. 2006. Trp-Arg-Trp-Trp-Trp-Trp antagonizes formyl peptide receptor like 2-mediated signaling. Biochem. Biophys. Res. Commun. 341: 1317-1322.
39. Zhou, C., S. Zhang, M. Nanamori, Y. Zhang, Q. Liu, N. Li, M. Sun, J. Tian, P. P. Ye, N. Cheng, R. D. Ye, and M. W. Wang. 2007. Pharmacological characterization of a novel nonpeptide antagonist for formyl peptide receptor-like 1. Mol. Pharmacol. 72: 976-983.
40. Migeotte, I., E. Riboldi, J. D. Franssen, F. Gregoire, C. Loison, V. Wittamer, M. Detheux, P. Robberecht, S. Costagliola, G. Vassart, et al. 2005. Identification and characterization of an endogenous chemotactic ligand specific for FPRL2. J. Exp. Med. 201: 83-93.
41. Gao, J. L., A. Guillabert, J. Hu, Y. Le, E. Urizar, E. Seligman, K. J. Fang, X. Yuan, V. Imbault, D. Communi, et al. 2007. F2L, a peptide derived from heme-binding protein, chemoattracts mouse neutrophils by specifically activating Fpr2, the low-affinity N-formylpeptide receptor. J. Immunol. 178: 1450-1456.
42. Lee, H. Y., S. Y. Lee, E. H. Shin, S. D. Kim, J. M. Kim, M. S. Lee, S. H. Ryu, and Y. S. Bae. 2007. F2L, a peptide derived from heme-binding protein, inhibits formyl peptide receptor-mediated signaling. Biochem. Biophys. Res. Commun. 359: 985-990.
43. Wan, H. X., C. Zhou, Y. Zhang, M. Sun, X. Wang, H. Yu, X. Yang, R. D. Ye, J. K. Shen, and M. W. Wang. 2007. Discovery of Trp-Nle-Tyr-Met as a novel agonist for human formyl peptide receptor-like 1. Biochem. Pharmacol. 74: 317-326.
44. Devosse, T., A. Guillabert, N. D'Haene, A. Berton, N. P. De, S. Noel, M. Brait, J. D. Franssen, S. Sozzani, I. Salmon, and M. Parmentier. 2009. Formyl peptide receptor-like 2 is expressed and functional in plasmacytoid dendritic cells, tissue-specific macrophage subpopulations, and eosinophils. J. Immunol. 182: 4974-4984.
45. Haas, P. J., C. J. C. de Haas, M. J. J. C. Poppelier, K. P. M. van Kessel, J. A. G. van Strijp, K. Dijkstra, R. M. Scheek, H. Fan, J. A. W. Kruijtzer, R. M. J. Liskamp, and J. Kemmink. 2005. The structure of the C5a receptorblocking domain of chemotaxis inhibitory protein of Staphylococcus aureus is related to a group of immune evasive molecules. J. Mol. Biol. 353: 859-872.
46. Rabiet, M. J., E. Huet, and F. Boulay. 2007. The N-formyl peptide receptors and the anaphylatoxin C5a receptors: an overview. Biochimie 89: 1089-1106.